Scintex

Scynexis is a biotechnology company focused on developing and commercializing innovative therapies to overcome and prevent difficult-to-treat and drug-resistant fungal infections. The company's lead product, Brexafemme (ibrexafungerp), is the first-of-its-kind triterpenoid antifungal approved for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. Scynexis is also advancing ibrexafungerp in several clinical programs for life-threatening fungal infections in hospital settings, including invasive candidiasis and refractory fungal infections. By targeting the fungal cell wall through a unique mechanism of action, the company aims to provide a much-needed alternative to existing antifungal classes like azoles and echinocandins.